Genetic disorders of Vitamin D biosynthesis and degradation

Journal of Steroid Biochemistry and Molecular Biology

Volumn 165, Issue , 2017, Pages 101-108

  Miller, Walter L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcium; CYP24A1; CYP27B1; CYP2R1; Neonatal hypercalcemia; Rickets; Secosteroid

Indexed keywords

CALCITRIOL; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); COLECALCIFEROL 24 HYDROXYLASE; OXYGENASE; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D 1ALPHA HYDROXYLASE; VITAMIN D 24 HYDROXYLASE; VITAMIN D 25 HYDROXYLASE; 7 DEHYDROCHOLESTEROL; 7-DEHYDROCHOLESTEROL; CALCIDIOL 1 MONOOXYGENASE; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; CYP24A1 PROTEIN, HUMAN; CYP27B1 PROTEIN, HUMAN; CYP2R1 PROTEIN, HUMAN; CYTOCHROME P450 FAMILY 2; STEROID;

BIOSYNTHESIS; CYP27B1 GENE; CYP2R1 GENE; DEGRADATION; ENZYME DEFICIENCY; GENE MUTATION; GENETIC DISORDER; HORMONE SUBSTITUTION; HUMAN; HYDROXYLASE DEFICIENCY; HYDROXYLATION; HYPOCALCEMIA; NONHUMAN; REVIEW; RICKETS; SECONDARY HYPERPARATHYROIDISM; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; ANIMAL; CELL PROLIFERATION; CHEMISTRY; DNA MUTATIONAL ANALYSIS; GENETICS; HYPERCALCEMIA; METABOLISM; MOUSE; MUTATION; RAT; ULTRAVIOLET RADIATION;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; CALCITRIOL; CELL PROLIFERATION; CHOLESTANETRIOL 26-MONOOXYGENASE; CHOLESTEROL; CHOLESTEROL SIDE-CHAIN CLEAVAGE ENZYME; CYTOCHROME P450 FAMILY 2; DEHYDROCHOLESTEROLS; DNA MUTATIONAL ANALYSIS; HUMANS; HYPERCALCEMIA; MICE; MUTATION; RATS; RICKETS; STEROIDS; ULTRAVIOLET RAYS; VITAMIN D; VITAMIN D3 24-HYDROXYLASE;

EID: 84964354391     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2016.04.001     Document Type: Review

References (108)

1. [1] Porter, F.D., Herman, G.E., Malformation syndromes caused by disorders of cholesterol synthesis. J. Lipid Res. 52 (2011), 6–34.
2. [2] Wassif, C.A., Zhu, P., Kratz, L., Krakowiak, P.A., Battaile, K.P., Weight, F.F., Grinberg, A., Steiner, R.D., Nwokoro, N.A., Kelley, R.I., Stewart, R.R., Porter, F.D., Biochemical, phenotypic and neurophysiological characterization of mouse model of RSH/Smith-Lemli-Opitz syndrome. Hum. Mol. Genet. 10 (2001), 555–564.
3. [3] Norman, A.W., Sunlight, season, skin pigmentation, vitamin D and 25-hydroxyvitamin D: integral components of the vitamin D endocrine system. Am. J. Clin. Nutr. 67 (1998), 1108–1110.
4. [4] Albright, F., Butler, A.M., Bloomberg, E., Rickets resistant to vitamin D therapy. Am. J. Dis. Child. 54 (1937), 529–547.
5. [5] Prader, A., Illig, R., Heierli, E., Eine besondere form des primare vitamin-D-resistenten rachitis mit hypocalcamie und autosomal-dominanten erbgang: die hereditare pseudomangelrachitis. Helv. Paediatr. Acta 16 (1961), 452–468.
6. [6] Scriver, C.R., Vitamin D dependency. Pediatrics 45 (1970), 361–363.
7. [7] Nebert, D.W., Wikvall, K., Miller, W.L., Human cytochromes P450 in health and disease. Phil Trans Roy Soc B, 368, 2013, 20120431.
8. [8] Miller, W.L., Regulation of steroidogenesis by electron transfer. Endocrinology 146 (2005), 2544–2550.
9. 3 25-hydroxylase from rat liver mitochondria. FEBS Lett. 262 (1990), 135–138.
10. 3: Gonadotropic regulation of the cognate mRNA in ovaries. DNA Cell Biol. 9 (1990), 657–665.
11. [11] Cali, J.J., Russell, D.W., Characterization of human sterol 27-hydroxylase. J. Biol. Chem. 266 (1991), 7774–7778.
12. [12] Cali, J.J., Hsieh, C.L., Franke, U., Russell, D.W., Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J. Biol. Chem. 266 (1991), 7779–7783.
13. [13] Leitersdorf, E., Reshef, A., Meiner, V., Lautzi, R., Schwartz, S.P., Dann, E.J., Berkman, N., Cali, J.J., Klapholz, L., Berginer, V.M., Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews of Moroccan origin. J. Clin. Invest. 91 (1993), 2488–2496.
14. [14] Gupta, R.P., Hollis, B.W., Patel, S.B., Patrick, K.S., Bell, N.H., CYP3A4 is a human vitamin D 25-hydroxylase. J. Bone Miner. Res. 19 (2004), 680–688.
15. [15] Yamasaki, T., Izumi, S., Ide, H., Ohyama, Y., Identification of a novel rat microsomal vitamin D3 25-hydroxylase. J. Biol. Chem. 279 (2004), 22848–22856.
16. [16] Rahmaniyan, M., Patrick, K., Bell, N.H., Characterization of recombinant CYP2C11: a vitamin D 25-hydroxylase and 24-hydroxylase. Am. J. Physiol. Endocrinol. Metab. 288 (2005), E753–E760.
17. [17] Zhu, J., DeLuca, H.F., Vitamin D 25-hydroxylase—Four decades of searching, are we there yet?. Arch. Biochem. Biophys. 523 (2012), 30–36.
18. [18] Bikle, D.D., Vitamin D metabolism, mechanism of action and clinical applications. Chem. Biol. 21 (2014), 319–329.
19. [19] Casella, S.J., Reiner, B.J., Chen, T.C., Holick, M.F., Harrison, H.E., A possible genetic defect in 25-hydroxylation as a cause of rickets. J. Pediatr. 124 (1994), 929–932.
20. [20] Abdullah, M.A., Salhi, H.S., Bakry, L.A., Okamoto, E., Abolmelha, A.M., Stevens, B., Mousa, F.M., Adolescent rickets in Saudi Arabia: a rich and sunny country. J. Pediatr. Endocrinol. Metab. 15 (2002), 1017–1025.
21. [21] Lin, C.J., Dardis, A., Wijesuriya, S.D., Abdullah, M.A., Casella, S.J., Miller, W.L., Lack of mutations in CYP2D6 and CYP27 in patients with apparent deficiency of vitamin D 25-hydroxylase. Mol. Genet. Metab. 80 (2003), 469–472.
22. [22] Cheng, J.B., Motola, D.L., Mangelsdorf, D.J., Russell, D.W., De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxylase. J Biol. Chem. 278 (2003), 38084–38093.
23. [23] Cheng, J.B., Levine, M.A., Bell, N.H., Mangelsdorf, D.J., Russell, D.W., Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. USA 101 (2004), 7711–7715.
24. [24] Dong, Q., Miller, W.L., Vitamin D 25-hydroxylase deficiency. Mol. Genet. Metab. 83 (2004), 197–198.
25. [25] Bieche, I., Narjoz, C., Asselah, T., Vacher, S., Marcellin, P., Lidereau, R., Beaune, P., de Waziers, I., Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics 17 (2007), 731–742.
26. [26] Thacher, T.D., Fischer, P.R., Singh, R.J., Roizen, J., Levine, M.A., CYP2R1 mutations impair generation of 25-hydroxyvitamin D and cause an atypical form of vitamin D deficiency. J. Clin. Endocrinol. Metab. 100 (2015), E1005–E1013.
27. [27] Al Mutair, A.N., Nasrat, G.H., Russell, D.W., Mutation of the CYP2R1 vitamin D 25-hydroxylase in a Saudi Arabian family with severe vitamin D deficiency. J. Clin. Endocrinol. Metab. 97 (2012), E2022–E2025.
28. [28] Zhu, J.G., Ochalek, J.T., Kaufmann, M., Jones, G., DeLuca, H.F., CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 15650–15655.
29. [29] Ahn, J., Yu, K., Stolzenberg-Solomon, R., Simon, K.C., McCullough, M.L., Gallicchio, L., Jacobs, E.J., Ascherio, A., Helzlsouer, K., Jacobs, K.B., Li, Q., Weinstein, S.J., Purdue, M., Virtamo, J., Horst, R., Wheeler, W., Chanock, S., Hunter, D.J., Hayes, R.B., Kraft, P., Albanes, D., Genome-wide association study of circulating vitamin D levels. Hum. Mol. Genet. 19 (2010), 2739–2745.
30. [30] Bu, F.X., Armas, L., Lappe, J., Zhou, Y., Gao, G., Wang, H.W., Recker, R., Zhao, L.J., Comprehensive association analysis of nine candidate genes with serum 25-hydroxy vitamin D levels among healthy Caucasian subjects. Hum. Genet. 2010:128 (2010), 549–556.
31. [31] Wang, T.J., Zhang, F., Richards, J.B., Kestenbaum, B., van Meurs, J.B., Berry, D., 70 co-authors, Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 376 (2010), 180–188.
32. [32] Elkum, N., Alkayal, F., Noronha, F., Ali, M.M., Melhem, M., Al-Arouj, M., Bennakhi, A., Behbehani, K., Alsmadi, O., Abubaker, J., Vitamin D insufficiency in Arabs and South Asians positively associates with polymorphisms in GC and CYP2R1 genes. PLoS One, 9(11), 2014, e113102.
33. [33] Nissen, J., Rasmussen, L.B., Ravn-Haren, G., Andersen, E.W., Hansen, B., Andersen, R., Mejborn, H., Madsen, K.H., Vogel, U., Common variants in CYP2R1 and GC genes predict vitamin D concentrations in healthy Danish children and adults. PLoS One, 9(2), 2014, e89907.
34. [34] Nissen, J., Vogel, U., Ravn-Haren, G., Andersen, E.W., Madsen, K.H., Nexø, B.A., Andersen, R., Mejborn, H., Bjerrum, P.J., Rasmussen, L.B., an Wulf HC: Common variants in CYP2R1 and GC genes are both determinants of serum 25-hydroxyvitamin D concentrations after UVB irradiation and after consumption of vitamin D3–fortified bread and milk during winter in Denmark. Am. J. Clin. Nutr. 101 (2015), 218–227.
35. [35] Barry, E.L., Rees, J.R., Peacock, J.L., Mott, L.A., Amos, C.I., Bostick, R.M., Figueiredo, J.C., Ahnen, D.J., Bresalier, R.S., Burke, C.A., Baron, J.A., Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. J. Clin. Endocrinol. Metab. 99 (2014), E2133–E2137.
36. [36] Zhou, Y., Zhao, L.J., Xu, X., Ye, A., Travers-Gustafson, D., Zhou, B., Wang, H.W., Zhang, W., Hamm, L.L., Deng, H.W., Recker, R.R., Lappe, J.M., DNA methylation levels of CYP2R1 and CYP24A1 predict vitamin D response variation. J. Steroid Biochem. Mol. Biol. 144 (2014), 207–214.
37. 3. J. Mol. Biol. 380 (2008), 95–106.
38. 3 24-hydroxylase. FEBS Lett. 278 (1991), 195–198.
39. 3 24-hydroxylase cDNA. Proc. Natl. Acad. Sci. U.S.A. 90 (1993), 4543–4547.
40. [40] Sakaki, T., Sawada, N., Komai, K., Shiozawa, S., Yamada, S., Yamamoto, K., Ohyama, Y., Inouye, K., Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur. J. Biochem. 267 (2000), 6158–6165.
41. 3-26,23-lactone, a vitamin D receptor antagonist that inhibits osteoclast formation and bone resorption in bone marrow cultures from patients with Paget's disease. Endocrinology 146 (2005), 2023–2030.
42. 3 receptor antagonists. Mol. Pharmacol. 59 (2001), 1478–1485.
43. [43] Chen, K.S., DeLuca, H.F., Cloning of the human 1α,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim. Biophys. Acta 1263 (1995), 1–9.
44. [44] Xie, Z.J., Munson, S.J., Huang, N., Portale, A.A., Miller, W.L., Bikle, D.D., The mechanism of 1,25-dihydroxyvitamin D3 auto-regulation in keratinocytes. J. Biol. Chem. 277 (2002), 36987–36990.
45. [45] Annalora, A.J., Goodin, D.B., Hong, W.X., Zhang, Q., Johnson, E.F., Stout, C.D., Crystal structure of CYP24A1, a mitochondrial P450 involved in vitamin D metabolism. J. Mol. Biol. 396 (2010), 441–451.
46. [46] Schlingmann, K.P., Kaufmann, M., Weber, S., Irwin, A., Goos, C., John, U., Misselwitz, J., Klaus, G., Kuwertz-Broking, E., Fehrenbach, H., Wingen, A.M., Guran, T., Hoenderop, J.G., Bindels, R.J., Prosser, D.E., Jones, G., Konrad, M., Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med. 365 (2011), 410–421.
47. [47] Streeten, E.A., Zarbalian, K., Damcott, C.M., CYP24A1 mutations in idiopathic infantile hypercalcemia. New Engl. J. Med. 365 (2011), 1741–1742.
48. [48] Dauber, A., Nguyen, T.T., Sochett, E., Cole, D.E.C., Horst, R., Abrams, S.A., Carpenter, T.O., Hirschhorn, J.N., Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J. Clin. Endocrinol. Metab. 97 (2012), E268–E274.
49. [49] Tebben, P.J., Milliner, D.S., Horst, R.L., Harris, P.C., Singh, R.J., Wu, Y., Foreman, J.W., Chelminski, P.R., Kumar, R., Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: Effects of ketoconazole therapy. J. Clin. Endocrinol. Metab. 97 (2012), E423–E427.
50. [50] Castanet, M., Mallet, E., Kottler, M.L., Lightwood syndrome revisited in a novel mutation in CYP24 and vitamin D supplement recommendations. J. Pediatr. 163 (2013), 1208–1210.
51. [51] Dinour, D., Beckerman, P., Ganon, L., Tordjman, K., Eisenstein, Z., Holtzman, E.J., Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J. Urol. 190 (2013), 552–557.
52. [52] Meusberger, E., Mundlein, A., Zitt, E., Obermayer-Pietsch, B., Kotzot, D., Lhotta, K., Medullary nephrocalcinosis in an adult patient with idiopathic infantile hypercalcemia and a novel CYP24A1 mutation. Clin. Kidney J. 6 (2013), 211–215.
53. [53] Jacobs, T.P., Kaufman, M., Jones, G., Kumar, R., Schlingmann, K.P., Shapses, S., Bilezikian, J.P., A lifetime of hypercalcemia and hypercalciuria, finally explained. J. Clin. Endocrinol. Metab. 99 (2014), 708–712.
54. [54] Mugg, A., Legeza, B., Tee, M.K., Damm, I., Long, R.K., Miller, W.L., Quantitation of CYP24A1 enzymatic activity with a simple two-hybrid system. J. Clin. Endocrinol. Metab. 100 (2015), 684–688.
55. [55] British Paediatric Association, Infantile hypercalcaemia, nutritional rickets and infantile scurvey in Great Britain. Brit. Med. J. i (1964), 1659–1661.
56. 3. J. Biol. Chem. 256 (1981), 7738–7740.
57. 3 by cultured pulmonary alveolar macrophages in sarcoidosis. J. Clin. Invest. 72 (1983), 1856–1860.
58. 3 production by human keratinocytes. J. Clin. Invest. 78 (1986), 557–566.
59. 3. Physiol. Rev. 64 (1984), 458–504.
60. 2D synthesis. Am. J. Med. Sci. 296 (1988), 417–425.
61. [61] Fu, G.K., Lin, D., Zhang, M.Y.H., Bikle, D.D., Miller, W.L., Portale, A.A., Cloning of human 25-hydroxyvitamin D-1α-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol. Endocrinol. 11 (1997), 1961–1970.
62. 3 1α-hydroxylase. Biochem. Biophys. Res. Commun. 239 (1997), 527–533.
63. [63] St-Arnaud, R., Messerlian, S., Moir, J.M., Omdahl, J.L., Glorieux, F.H., The 25-hydroxyvitamin D 1α-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J. Bone Miner. Res. 12 (1997), 1552–1559.
64. 3-1α-hydroxylase cDNA. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 12920–12925.
65. 3 1α-hydroxylase and vitamin D synthesis. Science 277 (1997), 1827–1830.
66. [66] Fu, G.K., Portale, A.A., Miller, W.L., Complete structure of the human gene for the vitamin D 1α-hydroxylase, P450c1α. DNA Cell Biol. 16 (1997), 1499–1507.
67. 3 1α-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N. Engl. J. Med. 338 (1998), 653–661.
68. [68] Yoshida, T., Monkawa, T., Tenenhouse, H.S., Goodyer, P., Shinki, T., Suda, T., Wakino, S., Hayashi, M., Saruta, T., Two novel 1α-hydroxylase mutations in French-Canadians with vitamin D dependency rickets type I. Kidney Int. 54 (1998), 1437–1443.
69. [69] Miller, W.L., Portale, A.A., Vitamin D 1α-hydroxylase. Trends Endocrinol. Metab. 11 (2000), 315–319.
70. [70] Fraser, D., Kooh, S.W., Kind, H.P., Holick, M.F., Tanaka, Y., DeLuca, H.F., Pathogenesis of hereditary vitamin-D-dependent rickets. An inborn error of vitamin D metabolism involving defective conversion of 25-hydroxyvitamin D to 1α,25-dihydroxyvitamin D. N. Engl. J. Med. 289 (1973), 817–822.
71. [71] Scriver, C.R., Reade, T.M., DeLuca, H.F., Hamstra AJ. Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N. Engl. J. Med. 299 (1978), 976–979.
72. [72] Wang, J.T., Lin, C.J., Burridge, S.M., Fu, G.K., Labuda, M., Portale, A.A., Miller, W.L., Genetics of vitamin D 1α-hydroxylase deficiency in 17 families. Am. J. Hum. Genet. 63 (1998), 1694–1702.
73. [73] Mandla, S., Jones, G., Tenenhouse, H.S., Normal 24-hydroxylation of vitamin D metabolites in patients with vitamin D-dependency rickets type I. Structural implications for the vitamin D hydroxylases. J. Clin. Endocrinol. Metab. 74 (1992), 814–820.
74. [74] De Braekeleer, M., Larochelle, J., Population genetics of vitamin D-dependent rickets in northeastern Quebec. Ann. Hum. Genet. 55 (1991), 283–290.
75. [75] Labuda, M., Morgan, K., Glorieux, F.H., Mapping autosomal recessive vitamin D dependency type I to chromosomal 12q14 by linkage analysis. Am. J. Hum. Genet. 47 (1990), 28–36.
76. [76] Labuda, M., Labuda, D., Korab-Laskowska, M., Cole, D.E., Zietkiewicz, E., Weissenbach, J., Popowska, E., Pronicka, E., Root, A.W., Glorieux, F.H., Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians. Am. J. Hum. Genet. 59 (1996), 633–643.
77. [77] Kim, C.J., Kaplan, L.E., Perwad, F., Huang, N., Sharma, A., Choi, Y., Miller, W.L., Portale, A.A., Mutations in the gene for 1α-hydroxylase, CYP27B1, in patients with vitamin D 1α-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 92 (2007), 3177–3182.
78. [78] Smith, S.J., Rucka, A.K., Berry, J.L., Davies, M., Mylchreest, S., Paterson, C.R., Heath, D.A., Tassabehji, M., Read, A.P., Mee, A.P., Mawer, E.B., Novel mutations in the 1α-hydroxylase (P450c1) gene in three families with pseudovitamin D-deficiency rickets resulting in loss of functional enzyme activity in blood-derived macrophages. J. Bone Miner. Res. 14 (1999), 730–739.
79. 3 1α-hydroxylase gene product in pseudovitamin D deficiency rickets, including that with mild clinical manifestation. J. Clin. Endocrinol. Metab. 84 (1999), 4111–4117.
80. [80] Wang, X., Zhang, M.Y.H., Miller, W.L., Portale, A.A., Novel gene mutations in patients with 1α-hydroxylase deficiency that confer partial enzyme activity in vitro. J. Clin. Endocrinol. Metab. 87 (2002), 2424–2430.
81. [81] Alzahrani, A.S., Zou, M., Baitei, E.Y., Alshaikh, O.M., Al-Rijjal, R.A., Meyer, B.F., Shi, Y., A novel G102E mutation of CYP27B1 in a large family with vitamin D-dependent rickets type 1. J. Clin. Endocrinol. Metab. 95 (2010), 4176–4183.
82. [82] Edouard, T., Alos, N., Chabot, G., Roughley, P., Glorieux, F.H., Rauch, F., Short- and long-term outcome of patients with pseudo-vitamin D deficiency rickets treated with calcitriol. J. Clin. Endocrinol. Metab. 96 (2011), 82–89.
83. [83] Cao, L., Liu, F., Wang, Y., Ma, J., Wang, S., Wang, L., Zhang, Y., Chen, C., Luo, Y., Ma, H., Novel vitamin D 1α-hydroxylase gene mutations in a Chinese vitamin-D-dependent rickets type I patient. J. Genet. 90 (2011), 339–342.
84. [84] Cui, N., Xia, W., Su, H., Pang, L., Jiang, Y., Sun, Y., Nie, M., Xing, X., Li, M., Wang, O., Yuan, T., Chi, Y., Hu, Y., Liu, H., Meng, X., Zhou, X., Novel mutations of CYP27B1 gene lead to reduced activity of 1α-hydroxylase in Chinese patients. Bone 51 (2012), 563–569.
85. [85] Durmaz, E., Zou, M., Al-Rijjal, R.A., Bircan, I., Akçurin, S., Meyer, B., Shi, Y., Clinical and genetic analysis of patients with vitamin D-dependent rickets type 1A. Clin. Endocrinol. 77 (2012), 363–369.
86. [86] Hu, W.W., Ke, Y.H., He, J.W., Fu, W.Z., Wang, C., Zhang, H., Yue, H., Gu, J.M., Zhang, Z.L., A novel compound mutation of CYP27B1 in a Chinese family with vitamin D-dependent ricketstype 1A. J. Pediatr. Endocrinol. Metab. 27 (2014), 335–341.
87. [87] Demir, K., Kattan, W.E., Zou, M., Durmaz, E., BinEssa, H., Nalbantoğlu, O., Al-Rijjal, R.A., Meyer, B., Özkan, B., Shi, Y., Novel CYP27B1 gene mutations in patients with vitamin D-dependent rickets type 1A. PLoS One, 10(7), 2015, e0131376.
88. [88] Füchtbauer, L., Brusgaard, K., Ledaal, P., Frost, M., Frederiksen, A.L., Case report: vitamin D-dependent rickets type 1 caused by a novel CYP27B1 mutation. Clin. Case Rep. 3 (2015), 1012–1016.
89. [89] Clifton-Bligh, R.J., Nguyen, T.V., Au, A., Bullock, M., Cameron, I., Cumming, R., Chen, J.S., March, L.M., Seibel, M.J., Sambrook, P.N., Contribution of a common variant in the promoter of the 1α-hydroxylase gene (CYP27B1) to fracture risk in the elderly. Calcif. Tissue Int. 88 (2011), 109–116.
90. [90] Ramagopalan, S.V., Dyment, D.A., Cader, M.Z., Morrison, K.M., Disanto, G., Morahan, J.M., Berlanga-Taylor, A.J., Handel, A., De Luca, G.C., Sadovnick, A.D., Lepage, P., Montpetit, A., Eberset, G.C., Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann. Neurol. 70 (2011), 881–886.
91. [91] Mast, N., Annalora, A.J., Lodowski, D.T., Palczewski, K., Stout, C.D., Pikuleva, I.A., Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1. J. Biol. Chem. 286 (2011), 5607–5613.
92. [92] Strushkevich, N., Mackenzie, F., Cherkesova, T., Grabovec, I., Usanov, S., Park, H.W., Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 10139–10143.
93. [93] Sawada, N., Sakaki, T., Kitanaka, S., Kato, S., Inouye, K., Structure-function analysis of CYP27B1 and CYP27A1: Studies on mutants from patients with vitamin D-dependent rickets type I (VDDR-I) and cerebrotendinous xanthomatosis (CTX). Eur. J. Biochem. 268 (2001), 6607–6615.
94. 3 1α-hydroxylase (CYP27B1) based on the crystal structure of rabbit CYP2C5. J. Steroid Biochem. Mol. Biol. 89 (2004), 167–171.
95. 3 whose mutation causes vitamin D-dependent rickets type 1. J. Biol. Chem. 280 (2005), 30511–30516.
96. 3 in vitamin D dependency. Pediatr. Res. 9 (1975), 593–599.
97. [97] Delvin, E.E., Glorieux, F.H., Marie, P.J., Pettifor, J.M., Vitamin D dependency: Replacement therapy with calcitriol. J. Pediatr. 99 (1981), 26–34.
98. [98] Miller, W.L., Hormone synthesis in mitochondria. Mol. Cell. Endocrinol. 379 (2013), 62–73.
99. [99] Slominski, A., Zjawiony, J., Wortsman, J., Semak, I., Stewart, J., Pisarchik, A., Sweatman, T., Marcos, J., Dunbar, C.C., Tuckey, R., A novel pathway for sequential transformation of 7-dehydrocholesterol and expression of the P450scc system in mammalian skin. Eur. J. Biochem. 271 (2004), 4178–4188.
100. [100] Slominski, A.T., Li, W., Kim, T.K., Semak, I., Wang, J., Zjawiony, J.K., Tuckey, R.C., Novel activities of CYP11A1 and their potential physiological significance. J. Steroid Biochem. Mol. Biol. 151 (2015), 25–37.
101. [101] Guryev, O., Carvalho, R.A., Usanov, S., Gilep, A., Estabrook, R.W., A pathway for the metabolism of vitamin D3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 14754–14759.
102. [102] Tuckey, R.C., Li, W., Shehabi, H.Z., Janjetovic, Z., Nguyen, M.N., Kim, T.K., Chen, J., Howell, D.E., Benson, H.A.E., Sweatman, T., Baldisseri, D.M., Slominski, A., Production of 22-hydroxy metabolites of vitamin D3 by cytochrome P450scc (CYP11A1) and analysis of their biological activities on skin cells. Drug Metab. Dispos. 39 (2011), 1577–1588.
103. [103] Slominski, A.T., Kim, T.K., Shehabi, H.Z., Semak, I., Tang, E.K.Y., Nguyen, M.N., Benson, H.A.E., Korik, E., Janjetovic, Z., Chen, J., Yates, C.R., Postlethwaite, A., Li, W., Tuckey, R.C., In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J. 26 (2012), 3901–3915.
104. [104] Slominski, A., Janjetovic, Z., Tuckey, R.C., Nguyen, M.N., Bhattacharya, K.G., Wang, J., Li, W., Jiao, Y., Gu, W., Brown, M., Postlethwaite, A.E., 20S-Hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. J. Clin. Endocrinol. Metab. 98 (2013), E298–E303.
105. [105] Slominski, A.T., Kim, T.K., Li, W., Yi, A.K., Postlethwaite, A., Tuckey, R.C., The role of CYP11A1 in the production of vitamin D metabolites and their role in the regulation of epidermal functions. J. Steroid Biochem. Mol. Biol. 144 (2014), 28–39.
106. [106] Slominski, A.T., Janjetovic, Z., Kim, T.K., Wasilewski, P., Rosas, S., Hanna, S., Sayre, R.M., Dowdy, J.C., Li, W., Tuckey, R.C., Novel non-calcemic secosteroids that are produced by human epidermal keratinocytes protect against solar radiation. J. Steroid Biochem. Mol. Biol. 148 (2015), 52–63.
107. [107] Tongkao-On, W., Carter, S., Reeve, V.E., Dixon, K.M., Gordon-Thomson, C., Halliday, G.M., Tuckey, R.C., Mason, R.S., CYP11A1 in skin: an alternative route to photoprotection by vitamin D compounds. J. Steroid Biochem. Mol. Biol. 148 (2015), 72–78.
108. [108] Tahir, S., Demirbilek, H., Ozbek, M.N., Baran, R.T., Tanriverdi, S., Hussain, K., Genotype and phenotype characteristics in 22 patients with vitamin D-dependent rickets type I. Horm. Res. Paedr., 2016, 10.1159/000444483 in press.